CRISABOROLE

/static/temp/default.svg Search structure
Trade Names
Synonyms
Status
Molecule Category UNKNOWN
ATC D11AH06
UNII Q2R47HGR7P
EPA CompTox DTXSID10238231

Structure

InChI Key USZAGAREISWJDP-UHFFFAOYSA-N
Smiles N#Cc1ccc(Oc2ccc3c(c2)COB3O)cc1
InChI
InChI=1S/C14H10BNO3/c16-8-10-1-3-12(4-2-10)19-13-5-6-14-11(7-13)9-18-15(14)17/h1-7,17H,9H2

Physicochemical Descriptors

Property Name Value
Molecular Formula C14H10BNO3
Molecular Weight 251.05
AlogP None
Hydrogen Bond Acceptor None
Hydrogen Bond Donor None
Number of Rotational Bond None
Polar Surface Area None
Molecular species None
Aromatic Rings None
Heavy Atoms None

Bioactivity

Mechanism of Action Action Reference
Phosphodiesterase 4 inhibitor INHIBITOR PubMed PubMed
Protein: Phosphodiesterase 4
Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4A
Organism : Homo sapiens
P27815 ENSG00000065989
Protein: Phosphodiesterase 4
Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4B
Organism : Homo sapiens
Q07343 ENSG00000184588
Protein: Phosphodiesterase 4
Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4C
Organism : Homo sapiens
Q08493 ENSG00000105650
Protein: Phosphodiesterase 4
Description: cAMP-specific 3',5'-cyclic phosphodiesterase 4D
Organism : Homo sapiens
Q08499 ENSG00000113448
Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Phosphodiesterase Phosphodiesterase 1 Phosphodiesterase 1A
- 6100 - - -
Enzyme Phosphodiesterase Phosphodiesterase 3 Phosphodiesterase 3A
- 6400 - - -
Enzyme Phosphodiesterase Phosphodiesterase 3 Phosphodiesterase 3B
- 6400 - - -
Enzyme Phosphodiesterase Phosphodiesterase 4 Phosphodiesterase 4A
- 110-490 - - -
Enzyme Phosphodiesterase Phosphodiesterase 4 Phosphodiesterase 4B
- 110-490 - - -
Enzyme Phosphodiesterase Phosphodiesterase 4 Phosphodiesterase 4C
- 110-490 - - -
Enzyme Phosphodiesterase Phosphodiesterase 4 Phosphodiesterase 4D
- 110-490 - - -
Enzyme Phosphodiesterase Phosphodiesterase 7 Phosphodiesterase 7A
- 730 - - -
Assay Description Organism Bioactivity Reference
Inhibition of PDE4 in human U937 cells assessed as accumulation of [3H]adenosine by scintillation counting Homo sapiens 490.0 nM
Antiinflammatory activity in human PBMC assessed as inhibition of LPS-induced TNFalpha release in after 24 hrs by FACS Array analysis Homo sapiens 540.0 nM
Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IL2 release after 24 hrs by FACS Array analysis Homo sapiens 610.0 nM
Antiinflammatory activity in human PBMC assessed as inhibition of phytohemagglutininin-induced IFN-gamma release after 24 hrs by FACSArray analysis Homo sapiens 830.0 nM
Inhibition of human recombinant PDE4 catalytic domain expressed in baculovirus-infected insect Sf9 cells by modified two-step method Homo sapiens 110.0 nM
Inhibition of human recombinant PDE7A1 expressed in baculovirus-infected insect Sf9 cells by modified two-step method Homo sapiens 730.0 nM
Antiinflammatory activity in mouse ear edema model assessed as inhibition of PMA-induced ear edema at 1 mg/ear administered 2 times 30 mins before and 15 mins after PMA challenge measured after 6 hrs of PMA application relative to control Mus musculus 78.0 %
Inhibition of PDE4 None 490.0 nM
Inhibition of PDE4A1A (unknown origin) Homo sapiens 55.0 nM
Inhibition of PDE4B1 (unknown origin) Homo sapiens 55.0 nM
Inhibition of PDE4B2 (unknown origin) Homo sapiens 55.0 nM
Inhibition of PDE4C1 (unknown origin) Homo sapiens 55.0 nM
Inhibition of PDE4D7 (unknown origin) Homo sapiens 55.0 nM
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of Caco-2 cells at 10 uM after 48 hours by high content imaging Homo sapiens 2.27 %
SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 7.43 % SARS-CoV-2 3CL-Pro protease inhibition percentage at 20µM by FRET kind of response from peptide substrate Severe acute respiratory syndrome coronavirus 2 -0.9307 %
Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.8 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.08 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.8 % Antiviral activity determined as inhibition of SARS-CoV-2 induced cytotoxicity of VERO-6 cells at 10 uM after 48 hours exposure to 0.01 MOI SARS CoV-2 virus by high content imaging Chlorocebus sabaeus 0.08 %
Inhibition of PDE4 (unknown origin) Homo sapiens 490.0 nM
Inhibition of PDE4B (unknown origin) assessed as hydrolysis of [3H]-cGMP into [3H]-GMP incubated for 30 mins by scintillation of proximity assay Homo sapiens 57.2 nM
Antiinflammatory activity against PMA-induced ICR mouse ear oedema model assessed as reduction in ear swelling at 1 mg/ear topically administered and measured after 4 hrs Mus musculus 43.55 %
Inhibition of Klebsiella pneumoniae KPC-2 Klebsiella pneumoniae 670.0 nM

Cross References

Resources Reference
ChEBI 134677
ChEMBL CHEMBL484785
DrugBank DB05219
DrugCentral 5201
FDA SRS Q2R47HGR7P
Guide to Pharmacology 9151
PubChem 44591583
SureChEMBL SCHEMBL595261
ZINC ZINC000169748244
CONTENTS